Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $265.19 -0.83%
EPS Growth %: -39.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: -39.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Truist Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
